436 related articles for article (PubMed ID: 34716979)
1. Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Enomoto T; Abe M; Okamoto A; Nagasawa T; Oishi T; Nagase S; Mori M; Inokuchi Y; Kamiura S; Komiyama S; Takeshima N; Sugiyama T
Cancer Sci; 2022 Jan; 113(1):240-250. PubMed ID: 34716979
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
4. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
9. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Nanki Y; Nomura H; Iwasa N; Saotome K; Dozen A; Yoshihama T; Hirano T; Hashimoto S; Chiyoda T; Yamagami W; Kataoka F; Aoki D
Jpn J Clin Oncol; 2021 Jan; 51(1):54-59. PubMed ID: 32776094
[TBL] [Abstract][Full Text] [Related]
10. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
12. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM; Siegel ER; Buza N; Bellone S; Silasi DA; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Rao GG; Reader JC; Hui P; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Santin AD
Br J Cancer; 2022 Jun; 126(12):1695-1703. PubMed ID: 35149854
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]